Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today ...
The FDA clearance follows the presentation of SANSA clinical performance data earlier this year at the SLEEP meeting. The study, drawing on data collected from 325 patients across 7 clinical sites, ...
(NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased ...
Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first ...
Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, ...
Successful product launches rely on more than just scientific excellence or commercial savvy—they demand seamless collaboration between medical and commercial teams. These functions, while distinct, ...
Microbot Medical is expanding its team ahead of the anticipated U.S. launch of the LIBERTY Endovascular Robotic System in Q3 2025. Microbot Medical Inc. announced the expansion of its commercial team ...
Outset Medical raises 2025 revenue guidance to $122M-$126M while advancing commercial transformation
Raised full-year 2025 revenue guidance from $115 million-$125 million to $122 million-$126 million. Gaeta stated, "We are very confident in our outlook and yet intend to maintain a level of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback